Overview

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment

Status:
Recruiting

Trial end date:
2026-06-23

Target enrollment:

Participant gender:

Summary

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis resistant to conventional therapy and without the BRAF gene mutation or after the failure of vemurafenib treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Anna Raciborska

Collaborators:

Łukasiewicz Research Network
Maria Sklodowska-Curie Institute - Oncology Center
Wrocław University of Environmental and Life Sciences

Treatments:

Trametinib